BIXLENVO FDA approval date

The FDA approved BIXLENVO on 27 Aug 2026.

FDA approval date
27 Aug 2026

Drug identity has not yet been verified against registry records

Also recorded as BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-08-27DayBIXLENVOFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA221104", "applicant_as_listed_by_fda": "GILEAD SCIENCES INC", "brand_names": ["BIXLENVO"], "active_ingredients": ["BICTEGRAVIR SODIUM", "LENACAPAVIR SODIUM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260827", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026